Cost-Effectiveness Analysis of Obeticholic Acid For The Treatment of Primary Biliary Cholangitis (PBC) Patients With Inadequate Response or Intolerance To Ursodeoxycholic Acid (UDCA) In France

Abstract

disease activity measured by adjusted mean SLEDAI (AMS), flares, and probability of organ damage progression are modelled separately for each health state and dynamically updated each cycle. Health state costs and utilities are based on multivariate regression analyses that increment payoffs for each cycle. Results: A new CEM framework was developed within a Markov model, which further allowed incorporation of AMS, flares and organ damage progression in SLE. Total costs and outcomes were similar to the previous CEM. ConClusions: This modelling study has simplified clinical assumptions of SLE to produce a Markov model that may be used by additional stakeholders due to its increased transparency and shorter run time. Study funded by GSK.

Comparação da eficácia terapêutica entre o ácido ursodesoxicólico manipulado e sua apresentação comercial na colangite biliar primária: avaliação dos eventos adversos e custos do tratamento

“…Mesmo com o uso do AUDC alguns pacientes, cerca de 40%, tem uma resposta bioquímica inadequada ao tratamento para CBP (54,55) . O Ácido obeticólico foi recentemente aprovado pela Food and Drug Administration (FDA) como terapia complementar ou em monoterapia (intolerantes ao AUDC) e tem demonstrado efeitos positivos nos marcadores de função hepática (29,55) .…”